Stock · BMY · Healthcare
United States · Large Cap · listed since 1972 · Revenue 12 mo. $49.2B
Price as of 11/06/2026
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Original text from the data provider
Summary
52.6 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
Required FCF growth per year
no growth
no growth afterwards
Price to operating cash flow 10.0×, within its usual range.
Middle half of 20 quarters: 7.6× to 10.0×, median 8.6×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
6 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, Net debt, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 38.19% | 11.52% | Rank 92 |
| Return on capital (Greenblatt) | 90.90% | 32.55% | Rank 89 |
| EBIT margin | 28.48% | 18.31% | Rank 81 |
| FCF margin | 26.65% | 14.12% | Rank 88 |
| Gross margin | 71.08% | 60.99% | Rank 70 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | −0.22% | 8.04% | Rank 12 |
| Earnings growth, 3 years per year | 5.44% | 5.44% | Rank 50 |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 2.72% | 3.66% | Rank 32 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 5.56% | 2.90% | Rank 84 |
| FCF yield | 10.20% | 3.63% | Rank 95 |
| EV/saleslower is better | 3.37 | 4.03 | Rank 56 |
| EV/EBITlower is better | 11.83 | 21.73 | Rank 88 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 23.66% | 8.66% | Rank 72 |
| Share price, 6 months | 11.13% | 24.27% | Rank 28 |
| Share price, 3 months | 1.14% | 15.42% | Rank 16 |
| Distance from 52-week high | −8.74% | −7.35% | Rank 44 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −3.25% | 0.30% | Rank 81 |
| Change in share countlower is better | 0.69% | 0.00% | Rank 16 |
| Dividend streak in years | 4 | 10 | Rank 46 |
| Price reaction to results, market-adjusted | 1.40% | 0.05% | Rank 62 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 20.52% | 48.40% | Rank 8 |
| Net debt/EBITDAlower is better | 2.39 | 1.11 | Rank 25 |
| Debt to equitylower is better | 2.55 | 0.48 | Rank 4 |
| Volatility, 1 yearlower is better | 27.53% | 31.42% | Rank 77 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 19.4 | 23.0% | 1.8 | 1.68B | $2.5B |
| 2017 | 20.8 | 16.6% | 4.2 | 1.65B | $2.5B |
| 2018 | 22.6 | 22.7% | 6.1 | 1.64B | $438.0M |
| 2019 | 26.1 | 22.6% | 7.2 | 1.71B | $35.2B |
| 2020 | 42.5 | 5.1% | 13.3 | 2.26B | $37.1B |
| 2021 | 46.4 | 18.4% | 15.2 | 2.25B | $31.6B |
| 2022 | 46.2 | 19.7% | 11.9 | 2.15B | $31.6B |
| 2023 | 45.0 | 18.2% | 12.7 | 2.08B | $30.0B |
| 2024 | 48.3 | 12.2% | 13.9 | 2.03B | $40.9B |
| 2025 | 48.2 | 28.5% | 12.8 | 2.04B | $36.9B |
5 of 7 StockScorer Score rules met · How the score is built
Bristol-Myers Squibb Company mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Bristol-Myers Squibb Company is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
5 of 7 rules met
8 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Bristol-Myers Squibb Company.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 18.0 | 30.0 |
| P/B ratio | 6.9 | 4.8 |
| Return on equity (ROE) | 38.2% | 11.5% |
| Equity ratio | 20.5% | 48.4% |
| Debt-to-equity (D/E) | 2.55 | 0.48 |
| Dividend yield | 4.1% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| BMY | Bristol-Myers Squibb Companythis page | |
| PFE | Pfizer Inc | Medium5.5 |
| GILD | Gilead Sciences Inc | High8.2 |
| BIIB | Biogen Inc | Low4.5 |
| AMGN | Amgen Inc | locked |
| MRK | Merck & Company Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.